Physician profile
Nancy Elmann
NPI 1184951030
$12,096.47
in general payments reported to CMS, 2019-2025
18 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $922 · 2022: $7,619 · 2023: $1,609 · 2024: $1,277 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550 · Honoraria: $1,000 · Education: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.53 |
| Honoraria | $1,000.00 |
| Education | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $7,381.50 | 2021-2025 | Optimizer, Optimizer |
| Abbott Laboratories | $3,519.74 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Edwards Lifesciences Corporation | $237.10 | 2022 | |
| Novo Nordisk INC | $194.11 | 2024-2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.82 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $112.25 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.87 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $79.31 | 2022-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $53.75 | 2024-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $45.25 | 2021-2022 | |
| Daiichi Sankyo INC. | $40.75 | 2024 | Vanflyta, Injectafer |
| Bridgebio Pharma, INC. | $35.84 | 2025 | Attruby |
| Endotronix, INC. | $31.17 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Lexicon Pharmaceuticals, INC. | $29.30 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $21.67 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $18.84 | 2025 | |
| United Therapeutics Corporation | $18.48 | 2025 | Tyvaso |
| Pfizer INC. | $16.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Elmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.